<DOC>
	<DOCNO>NCT00610038</DOCNO>
	<brief_summary>The aim trial try switch patient permanent neonatal diabetes mellitus due Kir6.2 SUR1 activate mutation subcutaneous insulin oral glibenclamide therapy .</brief_summary>
	<brief_title>Efficacy Safety Study Sulfonylureas Neonatal Diabetes Mellitus</brief_title>
	<detailed_description>Neonatal diabetes mellitus , characterize hyperglycaemia require exogenous insulin therapy appear first month life , rare condition estimate incidence 1 400000 newborn permanent one-half patient [ 1 ] . Several study identify heterozygous activate mutation cod sequence KCNJ11 ABCC8 patient permanent neonatal diabetes mellitus [ 5,6,7,8 ] . These gene encode 2 type subunit Kir6.2 SUR1 pancreatic Î²-cell ATP-sensitive K+ channel ( KATP channel ) play central role glucose-stimulating insulin secretion . These channel also find muscle nervous cell , may explain neurological feature sometimes associated permanent neonatal diabetes mellitus . Some sulfonylurea , glibenclamide , stimulate insulin secretion bind SUR1 subunit closing KATP channel ATP-independent mechanism . The glibenclamide use efficiently type 2 diabetes also recently replacement subcutaneous injected insulin child Kir6.2 SUR1 activate mutation [ 7,8,11-13 ] . The aim trial try switch patient permanent neonatal diabetes mellitus due Kir6.2 SUR1 activate mutation subcutaneous insulin oral glibenclamide therapy . This study stand Necker-Enfants Malades Hospital Endocrinology Diabetology Unit Professors Robert POLAK . It include 20 patient , already identify . This study two purpose : therapeutic switching patient subcutaneous insulin oral glibenclamide therapy , cognitive complementary evaluation understand mechanism insulin secretion glibenclamide efficiency . To , assess continuously capillary glycaemia three consecutive day evaluate insulin secretion insulin sulfonylurea . Furthermore , rate neurological developmental status patient seek potential improvement glibenclamide therapy . If oral glibenclamide therapy patient prove successful , systematic search Kir6.2 SUR1 activate heterozygous mutation newborn permanent neonatal diabetes mellitus could recommend order start early oral glibenclamide therapy thus extend indication sulfonylurea .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Infant , Newborn , Diseases</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>cod sequence KCNJ11 ABCC8 patient permanent neonatal diabetes mellitus write informed consent hypersensibility sulfonylureas severe renal failure ( clearance creatinemia &lt; 30 ml/min ) severe hepatic failure ( Prothrombin rate &lt; 70 % ) Porphyria imidazol treatment pregnancy social security affiliation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>neonatal</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>mutation</keyword>
	<keyword>KIR6.2</keyword>
	<keyword>SUR1</keyword>
	<keyword>Neonatal diabetes mellitus KIR6.2 SUR1 mutation</keyword>
</DOC>